Humans ; Melanocytes ; Melanosis ; Fibroblasts ; Skin

Humans ; Dyslipidemias ; HIV Infections/drug therapy* ; Risk Factors

Background: and Purpose Intracranial vertebrobasilar atherosclerotic stenosis (IVBAS) is a major cause of posterior circulation stroke. Some patients suffer from stroke recurrence despite receiving medical treatment. This study aimed to determine the prognostic value of a new score for the posterior communicating artery and the P1 segment of the posterior cerebral artery (PCoA-P1) for predicting stroke recurrence in IVBAS. Methods: We retrospectively enrolled patients with severe IVBAS (70%–99%). According to the number of stroke recurrences, patients were divided into no-recurrence, single-recurrence, and multiple-recurrences groups. We developed a new 5-point grading scale, with the PCoA-P1 score ranging from 0 to 4 based on magnetic resonance angiography, in which primary collaterals were dichotomized into good (2–4 points) and poor (0 or 1 point). Stroke recurrences after the index stroke were recorded. Patients who did not experience stroke recurrence were compared with those who experienced single or multiple stroke recurrences. Results: From January 2012 to December 2019, 176 patients were enrolled, of which 116 (65.9%) had no stroke recurrence, 35 (19.9%) had a single stroke recurrence, and 25 (14.2%) had multiple stroke recurrences. Patients with single stroke recurrence (odds ratio [OR]= 4.134, 95% confidence interval [CI]=1.822–9.380, p=0.001) and multiple stroke recurrences (OR=6.894, 95% CI=2.489–19.092, p<0.001) were more likely to have poor primary collaterals than those with no stroke recurrence. Conclusions The new PCoA-P1 score appears to provide improve predictions of stroke recurrence in patients with IVBAS.

Human immunodeficiency virus (HIV) infection causes severe systemic immune system damage and ultimately leads to patient death. Despite the success of anti-retroviral therapy (ART), which can effectively supress viral replication, there is currently no cure for HIV infection, which requires lifelong treatment. Due to the presence of HIV latent reservoir, the virus persists during antiretroviral treatment. "Shock and Kill" is currently one of the most recognized strategies for removing HIV latent reservoir. The solution is mainly to reactivate viral transcription by using latency-reversing agents (LRAs), which triggers cell lysis or immune-mediated clearance to kill the reactivated HIV infected cells and achieve functional cure. This article gives an overview of current research progress on HIV LRAs and their mechanism of action.

Humans ; Immune Checkpoint Inhibitors/therapeutic use* ; Prospective Studies ; HIV Infections/drug therapy* ; Anti-HIV Agents/therapeutic use* ; Comorbidity

Objective:To analyze the clinical characteristics and prognosis of patients with AIDS-related lymphoma (ARL).Methods:The clinical data of 84 patients with ARL admitted in the First Affiliated Hospital Zhejiang University School of Medicine from March 2013 to October 2021 were retrospectively reviewed, and the influencing factors for prognosis of patients were analyzed by Cox proportional risk regression model.Results:Non-Hodgkin’s lymphoma accounted for 95.2% (80/84) of all cases; 52.3% (44/84) of the patients presented with B symptoms of lymphoma such as fever, night sweats, and weight loss, and 84.5% (71/84) of them were classified as stage Ⅲ~Ⅳ by Ann Arbor staging; 58.0% (47/81) patients had CD4 + T cell count ≤200/μL at baseline; 30 (35.7%) patients had pulmonary infection, 11 (13.1%) patients had digestive tract infection, and 21.4% (18/84) patients had sepsis. The 1-year survival rate of 84 patients was 70.2% (59/84). Multivariate Cox survival analysis showed that International prognostic index (IPI) score >3 ( HR=5.094, 95% CI 1.877-13.824, P=0.001) was an independent risk factors and rituximab treatment ( HR=0.354, 95% CI 0.152-0.823, P=0.016) was an independent protective factor for the prognosis of patients with ARL. Conclusions:The clinical manifestations of ARL are diverse, and it is often diagnosed in the late stage of the disease with adverse prognosis. IPI score and Rituximab treatment are key prognostic factors in patients with ARL.